Data protection Impressum

R&D

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (September 2024)

30 September 2024

Switzerland maintains its position as the world’s most innovative economy in 2024, topping both the WIPO Global Innovation Index and the Roland Berger Innovation Indicator.

Switzerland continues to lead global innovation for the 14th consecutive year

30 September 2024

A Memorandum of Understanding (MOU) between KoreaBIO and the Switzerland Innovation Park West EPFL was signed during the Korea-Switzerland Partnering Day, strengthening industrial cooperation and joint research in biotech.

Switzerland strengthens biotech collaboration with KoreaBIO through new MOU

30 September 2024

Actival, a start-up supported by CSEM, has developed 3D-printed transparent aligners with antibacterial microchannels, setting a new standard in dental hygiene.

Actival and CSEM launch 3D-printed antibacterial dental aligners

23 September 2024

HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments to advance RNA-guided therapies for obesity and metabolic disorders.

HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery

17 September 2024

Empa researcher Mirko Kovac has been appointed as Professor of Sustainability Robotics at EPFL, marking a new collaboration aimed at developing cutting-edge drone and robotic technology for environmental and construction applications.

Joint professorship in robotics between EPFL and Empa to promote sustainability research

17 September 2024

Scientists from the University of Geneva and the University of Fribourg have made significant strides in understanding how yeast cells sense and respond to physical stress on their membranes, shedding light on the critical role of membrane dynamics in cell survival.

UNIFR and UNIGE collaborate on breakthrough research in cell membrane dynamics

14 August 2024

Release Therapeutics has raised CHF 3.3 million in seed funding to advance its innovative approach to treating metachromatic leukodystrophy (MLD), a rare genetic disorder affecting young children.

Release Therapeutics secures CHF 3.3 million to advance MLD research

13 August 2024

CSEM, along with start-ups Impli and Yalosys, has developed CERES, an implantable biosensor for real-time fertility hormone monitoring.

CSEM develops a pioneering implant to support reproductive medicine

7 August 2024

AC Immune’s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

AC Immune receives FDA Fast Track designation for Alzheimer’s disease therapy

6 August 2024

1 2 3 4 5 6 7 8 9 … 14